The market trends in Guillain-Barré Syndrome (GBS) represent a blend of several factors, which include advances in medical research, better diagnostic modalities and increased knowledge about autoimmune diseases. Increasing prevalence and recognition of GBS cases across the globe is one notable trend. As more people get to know this rare neurological disorder, medical professionals are able to identify and diagnose GBS better than before leading to a steady increase in reported cases. Given that the syndrome is progressive, such heightened awareness becomes vital for timely intervention and management.
The use of advanced diagnostic technologies, especially neuro-imaging studies and electrophysiological studies has resulted in improved accuracy as well as early detection of GBS. Magnetic Resonance Imaging (MRI) and nerve conduction studies are important tests used to confirm diagnosis and determine extent of nerve damage. This trend ensures a finer grasp on the disease for prompt medical intervention as well as personalized treatment plans for individuals affected by GBS.
Increased research activities targeted at GBS have resulted from pharmaceutical industry’s focus on rare diseases. Emergence of new therapeutic approaches such as immunomodulatory therapies has been necessitated by the search for effective therapeutic options against it. Plasmapheresis or intravenous immunoglobulin (IVIG) are usual ways through which GBS gets treated while ongoing investigations mainly aim at improving them further so that they can be applied more widely. This shows that there is an increasing commitment towards finding innovative solutions to managing GBS leading to better outcomes for patients.
Patient centric care approach coupled with quality-of-life considerations have become critical aspects in managing GBS today. Thus, there is a noticeable shift towards multidisciplinary care involving neurologists, physiotherapists, occupational therapists besides other health professional practitioners aimed at addressing not only neurological issues but also rehabilitation and long-term care needs among people suffering from the condition similar to example one above. There is an uptrend in the recognition of GBS as a complex condition, which demands comprehensive care hence leading to development of specialized treatment centers and programs.
Market trends are now being influenced by collaborations between patient advocacy groups, healthcare organizations and pharmaceutical companies. Awareness raising, research support and providing platforms for sharing experiences among those affected by GBS are some of the contributions made by these partnerships. Policy changes, early diagnosis promotion and creation of a supportive environment for GBS patients as well as their families can be achieved through joint efforts from all these key stakeholders.
Telemedicine has become important in the management of GBS. They facilitate remote consultations, monitoring and rehabilitation programs that can be performed using special software applications installed on smartphones or personal computers. Use of telemedicine technology assists patients to access specialised care even when they live far away from urban areas. This trend is aligned with general digital health shift tendencies, suggesting flexible approaches that focus more on the patient’s comfort in managing GBS.
Increased research into etiology has been prompted by the potential link between certain infections such as Zika virus and Campylobacter with development of Guillain-Barré syndrome (GBS). In order to develop tailored preventive measures, it is vital to know what causes or increases risk factors for this disease. This trend towards exploring connections between infections and GBS enables us to better understand the syndrome itself thus informing public health policies accordingly.
The guillain-barre syndrome market is projected to reach USD 608.62 Million by 2030 at 5.20% CAGR during the forecast period 2022-2030.Guillain-Barre Syndrome is a rare immune system disorder. In this medical condition, the patients’ immune system attacks their nervous system. The causative agents of the Guillain-Barre Syndrome are unknown. However, it is illuminated that the disease is often accompanied by infections including respiratory infection and stomach flu. The weakness of legs, difficulty in breathing, low or high blood pressure, difficulty with eye or facial movements is some of the common symptoms of the Guillain-Barre Syndrome.
The increasing prevalence of the Guillain-Barre Syndrome is expected to be one of the major drivers for the market growth during the forecast period. According to a study published by the PLOS One Journal in 2017, Guillain-Barre Syndrome is amongst some of the most common types of serious acute paralytic neuropathy. Moreover, it was estimated that about 100,000 new cases of the disease are reported, annually across the globe.
Additionally, growing geriatric population and increasing prevalence of chikungunya boost the market growth. According to the World Health Organization in 2016, about 349 936 suspected and 146,914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported most of the cases were Brazil (265,000 suspected cases), Bolivia, and Colombia (19,000 suspected cases). However, lack of awareness for the disease, absence of any definitive treatment, and low per capita healthcare expenditures in the middle- and low-income countries are estimated to restrain the market growth during the projected period.
Segmentation
The Guillain-Barre Syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the Guillain-Barre Syndrome Market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. On the basis of treatment, the market is segmented into plasmapheresis, medication, physical therapy, hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.
Research Methodology
Â
Sources: World Health Organization, PLOS One journal, Mayo Foundation for Medical Education and Research, Annual Reports, Press Release, White Paper, and Company Presentation
Regional Analysis
America dominates the Guillain-Barre Syndrome market in the presence of a well-developed healthcare sector and huge patient population. Moreover, the changing lifestyle and rising per capita healthcare expenditure fuel the market. Additionally, the presence of developed economies such as the U.S. and Canada within the region fuels the market growth.
Europe stands second in the Guillain-Barre Syndrome market. This can be attributed on the basis of availability of funds for research and a huge patient population. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region.
Asia Pacific is projected to be the fastest growing region for the Guillain-Barre syndrome market due to the presence of huge patient population and developing economies such as India and China within the region. Moreover, a growing healthcare sector and the growing government support boost the regional market for the Asia Pacific region.
On the other hand, the Middle East and Africa holds the least share of the global Guillain-Barre Syndrome Market. This can be attributed to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa is held by the Middle East owing to the increasing per capita healthcare expenditure by developed economies such as Dubai, Kuwait, and Saudi Arabia within the region.
Key Players in the Guillain-Barre Syndrome Market
The key players in the Guillain-Barre Syndrome Market are Grifols (Spain), Baxter (U.S.), CSL Behring (U.S.), Akari Therapeutics Plc (U.S.), ANNEXON, INC. (U.S.), Curavac (Europe), Hansa Medical (Sweden), Vitality Biopharma (U.S.), Covidien Limited (Republic of Ireland), Natus Medical Inc. (U.S.), Electrical Geodesics Inc. (U.S.), and others.
Intended Audience
Â
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)